Navigation Links
Cepheid Announces Accelerated Development of Flu A Panel Test
Date:9/9/2009

revention (CDC)."

Following EUA request to the FDA, development of Cepheid's Flu Panel test will continue by adding additional target identification for Flu B. For that product, a separate 510(k) submission is expected in 2010.

About the GeneXpert System

The GeneXpert System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples. Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands of any clinical environment.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those
'/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Reports 2009 Second Quarter Results
3. Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
4. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
5. Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
6. Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
7. Blue Mountain Quality Resources Announces that Cepheid has Selected Blue Mountain Regulatory Asset Manager
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Announces European Release of First On-Demand Molecular Pre-Surgical Screening Test for Simultaneous Detection of Methicillin-Sensitive and Resistant S. aureus
10. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, ... estimates member hospital ROI on membership dues at 12.5. In ... provides $12.50 in value to member hospitals. The calculation used ... Dues)/Member Dues. , “This is the first time we’ve ... think the methodology is really sound,” said Bill Ryan ...
(Date:10/20/2014)... Do you ever feel difficulty in ... wonderful app Metassessor for teachers, specialists and parents. SIMpalm, ... its client “Intervention Development LLC” to launch Metassessor App ... for iOS 4.3 or later and is Compatible with ... for iPhone 5. It is now available on Apple ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
(Date:10/19/2014)... 2014 Recently, Fancyflyingfox.com, an innovative company ... has announced its latest designs of 2014 mother ... new elegant outfits are offered with big discounts, up ... before October 30 can enjoy this special offer. ... strategies, it has become one of the leading brands ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... , CHARLOTTE, N.C., July 17 ... an affiliate of US HIFU -- a worldwide leader in ... focused ultrasound (HIFU) technologies -- officially launches Sonablate((R)) HIFU services ... Gandhi Cancer Institute & Research Centre (RGCI & RC) on ...
... Gene, brain activity may determine child,s temperament, study finds , ... easy baby or a fussy one may have nothing to ... certain gene and a particular pattern of brain activity may ... Canadian researchers examined the interaction between the DRD4 gene and ...
... remain volatile issues in the drive for bipartisan support , ... to overhaul the nation,s health-care system started to emerge from ... that this may, at long last, be the year that ... health care more affordable. , "I think we,re in a ...
... , DOYLESTOWN, Pa., July 17 The ... www.quigleyco.com , today announced that Ted Karkus, ... Executive Officer by the Board of Directors of the Company. The ... Chief Operating Officer. , , ...
... July 17 Masimo Corporation (Nasdaq: MASI ), ... pending litigation under which Masimo and Respironics will dismiss all claims and ... As part of the settlement, Respironics and Masimo have agreed upon ... , About Masimo , ...
... TSX: BMR , , TORONTO, July 17 /PRNewswire-FirstCall/ ... "Corporation") announced today that its Board of Directors has ... bid (the "Offer"), pursuant to which the Corporation will ... of its outstanding common shares ("Shares") at a price ...
Cached Medicine News:Health News:Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India 2Health News:Easy Baby or Fussy -- It May Be Out of Mom's Control 2Health News:Congress Braces for Showdown Over Health-Care Reform 2Health News:Congress Braces for Showdown Over Health-Care Reform 3Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 2Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 3Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 4Health News:Masimo Announces Settlement of Lawsuit 2Health News:Masimo Announces Settlement of Lawsuit 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 2Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 4
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014   BioNano ... the Irys system: the ability to collect human data at ... on a single chip.  This new capability was established and ... for the Irys TM System and will ... next two months. BioNano will be showcasing this advancement at ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs announces ... in Albany, NY for admixing, ... company meets and/or exceeds the FDA standards for safety ... CFR Part 211. The 10,000 square ... levels of quality assurance and quality control. The company ...
(Date:10/19/2014)... , October 20, 2014 Shire plc ... Bowling , Interim Chief Financial Officer (CFO), has notified the Board ... role to pursue a new career opportunity as CFO of Severn ... 2015 and the company will commence a search for a new ... "James has helped build and lead a high-quality finance ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5